Sec Form 3 Filing - Vairavan Latha @ Arcutis Biotherapeutics, Inc. - 2025-05-06

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Vairavan Latha 2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ ARQT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP Chief Financial Officer (Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300 3. Date of Earliest Transaction (MM/DD/YY) 05/06/2025 (Street) WESTLAKE VILLAGE, CA91361 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 45,104 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 17.67 ( 2 ) 03/03/2032 Common Stock 5,500 D Stock Option (right to buy) $ 15.82 ( 3 ) 03/02/2033 Common Stock 5,000 D Stock Option (right to buy) $ 3.64 ( 4 ) 01/12/2034 Common Stock 43,500 D Stock Option (right to buy) $ 13.69 ( 5 ) 02/28/2035 Common Stock 23,750 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Vairavan Latha C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE, CA91361 SVP Chief Financial Officer Signatures /s/ Masaru Matsuda, Attorney-in-Fact for Latha Vairavan 05/07/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents 2,225 Restricted Stock Units ("RSUs") granted on March 3, 2022 that vest on March 1, 2026; 4,050 RSUs granted on March 2, 2023 that vest as to 1/2 each on March 1, 2026 and 2027; 8,625 RSUs granted on January 12, 2024 that vest as to 1/3 each on February 1, 2026, 2027, and 2028; 713 RSUs granted on February 13, 2024 pursuant to option exchange program that vest as to 1/3 on each of August 1, 2025, November 1, 2025, and February 1, 2026; and 11,250 RSUs granted on February 28, 2025 that vest as to 1/4 each on March 1, 2026, 2027, 2028 and, 2029, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date. ( 2 )The option became exercisable as to 4,354 shares as of May 1, 2025. The remaining 1,146 of the 5,500 shares granted become exercisable in equal monthly installments on the first of every month, ending on March 1, 2026, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date. ( 3 )The option became exercisable as to 2,708 shares as of May 1, 2025. The remaining 2,292of the 5,000 shares granted become exercisable in equal monthly installments on the first of every month, ending on March 1, 2027, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date. ( 4 )The option became exercisable as to 13,594 shares as of April 12, 2025. The remaining 29,906 of the 43,500 shares granted become exercisable in equal monthly installments on the 12th of every month, ending on January 12, 2028, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date. ( 5 )The option became exercisable as to 990 shares as of May 1, 2025. The remaining 22,760 of the 23,750 shares granted become exercisable in equal monthly installments on the first of every month, ending on March 1, 2029, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.